Another high-quality project started, and Wujiang Development Zone accelerated
This morning (September 29), Suzhou Fangde Menda new drug development Co., Ltd. (hereinafter referred to as "Fangde Menda") ）The new thiscar-t product R & D and clinical production base project was started in Wujiang development zone. This marks a new page for Wujiang Development Zone to fully promote the high-quality development of life and health industry. Pan Hongliang, director of science and Technology Bureau of Wujiang Development Zone, and others attended the commencement ceremony.
Thiscar-t project launched this time is an innovative non gene editing universal car-t cell platform technology, which has a safe and good tumor inhibition effect on lymphoma patients. The project has broken through the bottleneck of the industrial production of allogeneic car-t cells, and is expected to take the lead in realizing the leap from expensive individual customization to shelf drugs.
Dr. Li Jun, general manager of Fangde Menda, said in his speech
The company will focus on the research and development of breakthrough tumor immune cell drugs, Focus on the Bottleneck Breakthrough of tumor immune cell therapy (ACT), and focus on the discovery, development, clinical treatment application and industrialization of global cellular drugs with the goal of first in accessibility and first in breakthrough. Fondemenda will submit two listing applications in three years or less (the first general-purpose cart product is listed, and the company is listed in the capital market), and complete a strategic cooperation with a project or product of multinational pharmaceutical enterprises.
Since this year, Wujiang Development Zone has consciously shouldered the mission of building the Yangtze River Delta integrated development demonstration zone and accelerating the urbanization of Shanghai and the Soviet Union, made full use of and gave full play to the advantages of regional medical resources, unblocked the communication channels between enterprises and colleges and universities, enterprises and the government, enterprises and finance, and enterprises and enterprises, and is committed to promoting the progress of biomedical technology and strengthening the supporting cooperation between upstream and downstream of the industrial chain, Spawn a number of original achievements, strive to break through a number of neck projects, strive to cultivate a number of leading enterprises, and strive to achieve high-quality development of life and health industry.
A ribbon cutting ceremony and a groundbreaking ceremony were held at the event site.